News

Teijin Pharma Limited and Astellas Pharma Inc. announced that they have entered into an exclusive distribution agreement for febuxostat (generic name, development code: TMX-67), a novel drug for...

Tokyo, July 28, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced today that it was granted approval for the additional indication...

Tokyo, July 22, 2011 – Astellas Pharma Inc. (“Astellas,” Tokyo: 4503) today announced that it will once again hold the “Changing Tomorrow Day” (CT Day) this year as part of its global...

Tokyo, July 14, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced today that Astellas and its Canadian affiliate Astellas Pharma...

Pfizer Japan Inc. (hereafter: Pfizer, Headquarters: Tokyo, President: Ichiro Umeda) and Astellas Pharma Inc. (hereafter: Astellas, Headquarters: Tokyo, President: Yoshihiko Hatanaka) today...

Osaka and Tokyo, Japan, July 1, 2011 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc. (“Astellas”;...

Tokyo, Japan, July 1, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) today announced that Betanis® tablet (generic name:mirabegron) was...

TOKYO, June 21, 2011 ─ Astellas Pharma Inc. (“Astellas”; Tokyo:4503) and Abbott Japan Co., Ltd. (“Abbott”) today announced that Astellas will transfer the rights to distribute the...

Japan, June 20, 2011 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka,“Astellas”) announces that today it appointed Yasumasa Masuda as Corporate Executive,...

Tokyo, April 26, 2011 – Asteallas Pharma Inc. (TOKYO: 4503, “Astellas”) expresses its deepest sympathy for those who have lost their lives and been displaced by the Eastern Japan Earthquake,...

Tokyo, April 20, 2011 - Astellas Pharma Inc. (TOKYO:4503,“Astellas”) announced that a new dosage form of Vesicare® (generic name: solifenacin succinate), the orally disintegrating tablet...

Tokyo, April 5, 2011 - Astellas Pharma Inc. (“Astellas”, TSE: 4503) expresses its deepest sympathy for those who have lost their lives and been displaced by the Eastern Japan Earthquake, which...

Tokyo, March 30, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and Pfizer Japan Inc. (“Pfizer”; Headquarters: Tokyo; President: Ichiro...

Tokyo, March 25, 2011, Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has established Astellas Pharma d.o.o. in Slovenia....

Tokyo, March 23, 2011 - Astellas Pharma Inc. (“Astellas”, TSE: 4503) expresses its deepest sympathy for those who have lost their lives and been displaced by the Tohoku Earthquake, which...

Tokyo, March 17, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has exercised a buy-out option to acquire all of...

Tokyo, March 16, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that OSI Pharmaceuticals, Inc. (a subsidiary of Astellas),...

Tokyo, March 15, 2011 - Astellas Pharma Inc. (“Astellas”, TSE: 4503) is currently assessing the impact of the Tohoku Earthquake upon its various facilities and provides details of current...

Tokyo, March 14, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it submitted a market authorization application for an...

Tokyo – February 16, 2011 – Astellas Pharma Inc. (TSE:4503,”Astellas”) announced today that its affiliate, Astellas Pharma US, Inc.(“Astellas Pharma US”) exercised its right under its...

Tokyo, February 15, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it withdrew a market authorization application for...

Tokyo, – February 3, 2011 – Astellas Pharma Inc. (TSE: 4503) announced today that it has established Astellas Pharma Australia Pty Ltd (“Astellas Australia”), in North Ryde (near Sydney),...

Tokyo, December 20, 2010 - Astellas Pharma Inc. (“Astellas”; headquarter: Tokyo; President and CEO: Masafumi Nogimori) announced today that it agreed with AstraZeneca UK Limited upon an...

Tokyo, December 10, 2010 - Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo, President & CEO: Masafumi Nogimori) today announced that a new organization is to be established within...

Maruho Co., Ltd. （Headquarters: Osaka, President & CEO: Koichi Takagi, hereafter referred to “Maruho”) and Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori,...